APYX on Nasdaq
Apyx Medical Corp
Price unavailable
Last updated Oct 18, 2026.
Overview
Compare with LENSAR, Inc., CARLSMED, INC. or CVRx (United States), or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
62.5%Gross margin3
-12.2%Operating margin3
-21.2%Net margin3
9.9%Revenue growth, 20253
-77.1%Return on equity3
2.40×Debt to equity3
-$9.1MFree cash flow3
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Business segments
Surgical Aesthetics brought in 86% of the revenue Apyx Medical Corp broke down this way in fiscal 2025.
Business segments by year
| Business segments | 2024 | 2025 |
|---|---|---|
| Surgical Aesthetics | $38.6M | $45.3M |
| OEM | $9.5M | $7.5M |
Regions
United States brought in 73% of the revenue Apyx Medical Corp broke down this way in fiscal 2025.
Regions by year
| Regions | 2024 | 2025 |
|---|---|---|
| United States | $34.0M | $38.8M |
| Outside the United States | $14.1M | $14.0M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue37¢$19.8M
- Research and development6¢$3.4M
- Selling, general and admin30¢$15.8M
- Other costs26¢$13.6M
- Income tax1¢$270.0K
Out of $52.8M in revenue.3 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Sales, net | $52.8M | $48.1M | |
| Cost of sales | $19.8M | $18.7M | |
| Gross profit | $33.0M | $29.4M | |
| Research and development | $3.4M | $5.1M | |
| Professional services | $6.3M | $6.9M | |
| Salaries and related costs | $14.0M | $17.4M | |
| Selling, general and administrative | $15.8M | $18.9M | |
| Total other costs and expenses | $39.5M | $48.2M | $53.7M |
| Loss from operations | -$6.4M | -$18.8M | |
| Interest income | $1.1M | $1.6M | |
| Interest expense | -$5.6M | -$5.9M | |
| Other Operating Income (Expense), Net | $92.0K | -$161.0K | |
| Total other expense, net | -$4.4M | -$4.5M | |
| Loss before income taxes | -$10.8M | -$23.3M | |
| Income tax expense | $270.0K | $252.0K | |
| Net loss | -$11.1M | -$23.6M | |
| Net loss attributable to non-controlling interest | $106.0K | -$96.0K | |
| Net loss attributable to stockholders | -$11.2M | -$23.5M | |
| Basic and diluted (in dollars per share) | -$0.27 | -$0.66 | |
| Weighted average number of shares outstanding - basic and diluted (in shares) | 41.1M shares | 35.5M shares |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2024-10-31 |
|---|---|---|---|
| Cash and cash equivalents | $31.7M | $31.7M | |
| Trade accounts receivable, net of allowance of $1,020 and $1,000 | $16.8M | $15.5M | |
| Inventories, net of provision for obsolescence of $1,207 and $1,032 | $8.6M | $7.6M | |
| Prepaid expenses and other current assets | $1.4M | $1.7M | |
| Total current assets | $58.5M | $56.4M | |
| Property and equipment, net | $2.4M | $2.0M | |
| Operating lease right-of-use assets | $4.2M | $4.7M | |
| Finance lease right-of-use assets | $28.0K | $48.0K | |
| Other assets | $1.8M | $1.7M | |
| Total assets | $66.8M | $64.8M | |
| Accounts payable | $3.1M | $2.6M | |
| Accrued expenses and other current liabilities | $8.2M | $7.8M | |
| Current portion of operating lease liabilities | $407.0K | $335.0K | |
| Current portion of finance lease liabilities | $21.0K | $20.0K | |
| Total current liabilities | $11.7M | $10.7M | |
| Long-term debt, net of debt discounts and issuance costs | $34.8M | $33.9M | |
| Long-term operating lease liabilities | $4.1M | $4.5M | |
| Long-term finance lease liabilities | $12.0K | $33.0K | |
| Long-term contract liabilities | $1.1M | $1.1M | |
| Other liabilities | $347.0K | $259.0K | |
| Total liabilities | $52.0M | $50.5M | |
| Preferred stock, $0.001 par value; 10,000,000 shares authorized; 0 issued and outstanding as of December 31, 2025 and December 31, 2024 | $0 | $0 | |
| Common stock, $0.001 par value; 75,000,000 shares authorized; 41,785,946 issued and outstanding as of December 31, 2025, and 37,793,886 issued and outstanding as of December 31, 2024 | $42.0K | $38.0K | |
| Additional paid-in capital | $103.6M | $92.1M | |
| Accumulated deficit | -$89.1M | -$77.9M | |
| Total stockholders equity | $14.5M | $14.2M | |
| Non-controlling interest | $291.0K | $125.0K | |
| Total equity | $14.8M | $14.3M | |
| Total liabilities and equity | $66.8M | $64.8M | |
| Allowance for credit loss | $1.0M | $1.0M | |
| Provision for obsolescence | $1.2M | $1.0M | |
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Preferred stock, authorized (in shares) | 10.0M shares | 10.0M shares | |
| Preferred stock, issued (in shares) | 0 shares | 0 shares | |
| Preferred stock, outstanding (in shares) | 0 shares | 0 shares | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | $0.00 |
| Common stock, authorized (in shares) | 75.0M shares | 75.0M shares | |
| Common stock, issued (in shares) | 41.8M shares | 37.8M shares | |
| Common stock, outstanding (in shares) | 41.8M shares | 37.8M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$11.1M | -$23.6M |
| Depreciation and amortization | $655.0K | $599.0K |
| Provision for inventory obsolescence | $341.0K | $163.0K |
| Provision for product warranties | $214.0K | $304.0K |
| Loss on disposal of property and equipment | $19.0K | $13.0K |
| Stock based compensation | $2.0M | $4.0M |
| Allowance for credit losses | $423.0K | $396.0K |
| Non-cash lease expense | $86.0K | $112.0K |
| Non-cash interest expense | $956.0K | $1.2M |
| Trade receivables | -$1.3M | -$2.0M |
| Prepaid expenses and other assets | $237.0K | $857.0K |
| Inventories | -$1.1M | $2.3M |
| Accounts payable | $355.0K | -$63.0K |
| Accrued and other liabilities | $209.0K | -$2.3M |
| Net cash used in operating activities | -$8.0M | -$18.0M |
| Purchases of property and equipment | -$1.1M | -$722.0K |
| Net cash used in investing activities | -$1.1M | -$722.0K |
| Proceeds from stock option exercises | $488.0K | $0 |
| Proceeds from capital raise | $9.3M | $7.0M |
| Payment of direct incremental costs in capital raise | -$248.0K | -$224.0K |
| Payment of debt costs | $0 | -$11.0K |
| Repayment of finance lease liabilities | -$20.0K | -$20.0K |
| Contributions from non-controlling interest | $60.0K | $0 |
| Net cash provided by financing activities | $9.6M | $6.7M |
| Net change in cash and cash equivalents | -$1.0K | -$11.9M |
| Effect of exchange rates on cash | -$466.0K | $113.0K |
| Interest | $4.6M | $4.7M |
| Income taxes | $258.0K | $382.0K |
| Fair value of common stock issued in debt amendment | $0 | $183.0K |
| Transfer of machinery and equipment to inventory | $78.0K | $62.0K |
Former names
Recent filings
- Sep 29, 20268-K
- Aug 7, 20268-K
- Aug 6, 20268-K
- Aug 6, 202610-Q
- Jul 24, 20268-K
- Jul 21, 2026SCHEDULE 13G/A
- Jul 2, 20264
- Jun 26, 2026DEF 14A
- Jun 17, 20268-K
- Jun 17, 20264
- Jun 15, 20264
- Jun 15, 20264
- Jun 15, 20264
- Jun 15, 20264
- Jun 15, 20264
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10